Core Viewpoint - Transgene, a biotech company specializing in virus-based immunotherapies for cancer treatment, has announced its financial reporting and annual shareholders' meeting dates for 2026 [1]. Financial Reporting Schedule - The company will release its 2025 Fiscal Year Results on March 24, 2026 [1]. - The First Quarter 2026 Financial Results will be announced on April 29, 2026 [1]. - The Annual Shareholders' Meeting is scheduled for May 13, 2026 [1]. - The First Half 2026 Financial Results will be disclosed on September 24, 2026 [1]. - The Third Quarter 2026 Financial Results will be reported on November 9, 2026 [1]. Company Overview - Transgene focuses on designing and developing targeted immunotherapies for cancer, with a portfolio of viral vector-based immunotherapeutics [2]. - The lead asset, TG4050, is the first individualized therapeutic vaccine based on the myvac® platform, showing proof of principle in treating head and neck cancers [2]. - Other assets include BT-001, an oncolytic virus in clinical development, and ongoing innovative discovery and preclinical work for novel immunotherapies [2]. Technological Innovation - The myvac® platform enables precision medicine through a tailored virus-based immunotherapy that incorporates patient-specific mutations identified by Artificial Intelligence in collaboration with NEC [3].

Core Viewpoint - Transgene has strengthened its Scientific Advisory Board by appointing two prominent scientific advisors, Prof. Antoine Italiano and Prof. Ignacio Melero, to enhance its leadership in cancer immunotherapy development [1][2]. Group 1: Company Overview - Transgene is a biotechnology company focused on designing and developing virus-based immunotherapies for cancer treatment, with a clinical-stage portfolio that includes the myvac® platform for individualized neoantigen therapeutic vaccines [10][11]. - The company’s lead asset, TG4050, has shown proof of principle in patients for the adjuvant treatment of head and neck cancers, and it is also developing other viral vector-based assets like BT-001 [10]. Group 2: Scientific Advisors - Prof. Antoine Italiano is a leading medical oncologist with expertise in early drug development and precision medicine, serving as Head of the Department of Medicine at Institut Bergonié and leading the Precision Medicine program at Gustave Roussy [2][3]. - He has been the Principal Investigator for over 50 Phase I trials and more than 40 Phase II and III clinical trials, focusing on immuno-oncology and targeted therapies [3][4]. - Prof. Ignacio Melero is a professor of immunology at the University of Navarra and co-director of the Department of Immunology and Immunotherapy, recognized for his work in cancer immunotherapy and immunostimulatory monoclonal antibodies [5][6]. - He has led over 40 clinical trials in immunotherapy and has published more than 350 scientific articles, receiving an ERC Advanced Grant for his research on mRNA-based immunotherapies [7][8].

Strasbourg, January 12, 2026 – 06:00 p.m. CET Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of December 31, 2025, the following resources were managed through the liquidity account: 304,479 shares€ 147,574.00 In the second half of 2025, a total of: Purchases348,958 shares€ 389,221.00988 market transactionsSales372,229 shares€ 424,419.001,278 market transactions It is recalled that when the liquidity program was initially established in 2016, the following resources were m ...

Core Insights - TG4050 demonstrates strong potential as an individualized cancer immunotherapy, showing 100% two-year disease-free survival in patients with operable head and neck cancers [3][5][8] Clinical Trial Results - The Phase I/II trial of TG4050 involved patients with HPV-negative head and neck squamous cell carcinoma (HNSCC), where one-third of patients typically experience recurrence within two years post-surgery [3] - Half of the participants received TG4050 immediately after primary adjuvant treatment, while the other half received it at the time of disease recurrence [4][16] - The trial results indicate that TG4050 can prevent cancer relapses when used as monotherapy in high-risk, resected, locally advanced HPV-negative HNSCC patients [5] Immunogenicity and T-cell Responses - TG4050 induced neoantigen-specific T-cell responses in 73% of evaluable patients, with these responses being durable for up to one year post-treatment [6][7] - The vaccine was well-tolerated, showing no unexpected safety signals, reinforcing its potential for further development [5][8] Publication and Transparency - The results of the Phase I trial have been published on medRxiv, emphasizing the company's commitment to transparency and scientific rigor [2][8] - The findings are currently under evaluation for publication in a peer-reviewed journal [2] Future Developments - TG4050 is undergoing further evaluation in a randomized Phase I/II clinical trial (NCT04183166), with first immunogenicity data from the Phase II part expected in the second half of 2026 [7][16]

Core Points - Transgene has requested the suspension of trading of its shares on Euronext Paris pending the publication of the results of its capital increase, with trading set to resume on 27 November 2025 [1] Company Overview - Transgene is a biotechnology company focused on developing targeted immunotherapies for cancer treatment, with a portfolio of viral vector-based immunotherapeutics [2] - The company's lead asset is TG4050, an individualized therapeutic vaccine based on the myvac® platform, which has shown proof of principle in treating head and neck cancers [2] - Transgene is also developing other viral vector-based assets, including BT-001, an oncolytic virus in clinical development, and is engaged in innovative discovery and preclinical work for novel viral vector-based modalities [2] Technology and Innovation - The myvac® platform allows for the creation of personalized virus-based immunotherapies that encode patient-specific mutations identified through advanced AI technologies [3] - Transgene's proprietary Invir.IO® platform is aimed at designing a new generation of multifunctional oncolytic viruses, leveraging the company's expertise in viral vector engineering [4]

Core Points - Transgene successfully raised approximately €105 million through a fundraising initiative involving private placements and retail offerings at a price of €1.02 per share [1][6][10] - The funds will primarily support the development of the myvac® platform, which focuses on individualized therapeutic vaccines for cancer treatment [4][5][7] - The fundraising included participation from specialized healthcare investors and existing shareholders, indicating strong institutional interest [2][21] Fundraising Details - The fundraising consisted of a private placement and a public offering via the PrimaryBid platform, with a total of 141,433,349 new ordinary shares issued, representing 106.5% of the company's current share capital [9][10] - The subscription price of €1.02 per share reflects a 25% discount compared to the closing price prior to the fundraising [10] - A reserved capital increase of €39,262,015.44 was also conducted for TSGH, utilizing amounts advanced under a current account advance agreement [3][12] Use of Proceeds - Approximately 70% of the net proceeds will be allocated to accelerate the myvac® program, including ongoing Phase 2 trials and the launch of new indications [7][5] - About 20% will be directed towards R&D costs related to the myvac® program and other clinical trials [7] - The remaining funds will cover general administrative expenses and recurring cash consumption [7] Expected Milestones - Key milestones include the completion of the ongoing Phase 2 trial in head and neck cancers, with results anticipated by late 2027 or early 2028 [4][15] - The company plans to launch a Phase 1 trial in a new indication and prepare for pivotal trials by the end of 2027 [15][4] Share Capital and Ownership Structure - Post-fundraising, the company's share capital will amount to €82,256,012.70, divided into 274,186,709 ordinary shares [18] - TSGH will hold 78.29% of the capital, while SITAM Belgium will hold 3.55%, with other shareholders comprising 18.16% [18][21] Trading and Regulatory Information - Trading of Transgene's shares on Euronext Paris was suspended during the fundraising and is set to resume on November 27, 2025 [23][24] - The new shares will be fungible with existing shares and will carry the same rights [25]

Core Points - Transgene has requested a suspension of trading for its shares on Euronext Paris starting November 26, 2025, pending the announcement of its capital increase results [1] - Trading is expected to resume on November 27, 2025, at market opening [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment, with a portfolio that includes several viral vector-based immunotherapies in clinical development [2] - The lead candidate, TG4050, is the first individualized treatment from the myvac® platform, showing clinical proof of concept in patients with head and neck cancer [2] - Other candidates in development include BT-001, an oncolytic virus based on the patented invir.IO® platform [2] Technology and Innovation - The myvac® platform integrates tumor mutations identified through artificial intelligence into a viral vector, marking a step into precision medicine [3] - The invir.IO® platform allows for the design of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [3]

Core Points - Transgene has requested a suspension of trading for its shares on Euronext Paris pending the publication of results from its capital increase [1] - Trading is expected to resume on November 27, 2025, at the market opening [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment [2] - The company's lead candidate, TG4050, is an individualized treatment that has shown clinical proof of concept in patients with head and neck cancer [2] - Transgene is also developing other candidates, including BT-001, which is based on a patented oncolytic virus [2] Technology Platforms - The myvac® platform allows for patient-specific immunotherapy by integrating tumor mutations identified through artificial intelligence [3] - The invir.IO® platform enables the design of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [3]

Core Viewpoint - Transgene has requested a suspension of trading for its shares on Euronext Paris pending the announcement of its capital increase results, with trading expected to resume on November 27, 2025 [1] Company Overview - Transgene is a biotechnology company focused on developing immunotherapy products for cancer treatment, with a portfolio that includes several viral vector-based immunotherapies currently in clinical development [3] - The lead candidate, TG4050, is the first individualized treatment from the myvac® platform, showing clinical proof of concept in patients with head and neck cancer [3] - Other candidates in development include BT-001, an oncolytic virus based on the patented invir.IO® platform [3] Technology and Innovation - The myvac® platform integrates tumor mutations identified through artificial intelligence into a viral vector, marking a step into precision medicine [4] - The invir.IO® platform allows for the design of a new generation of multifunctional oncolytic viruses, showcasing Transgene's expertise in viral vector engineering [4]

Core Points - Transgene is launching a fundraising initiative to raise approximately €105 million through the issuance of new shares to specialized investors via private placement and to retail investors via the PrimaryBid platform [1][4][6] - The funds raised will primarily accelerate the development of the myvac® program, which focuses on individualized cancer vaccines, particularly for head and neck cancer [3][4][7] - The company anticipates that the net proceeds from the fundraising, combined with existing cash, will be sufficient to meet working capital requirements until early 2028 [5][9] Fundraising Details - The fundraising consists of a private placement aimed at international institutional investors and a public offering for retail investors, with TSGH committing to subscribe for at least €70 million [6][10] - A concurrent capital increase of approximately €39.4 million is reserved for TSGH, which will be executed at the same price as the private placement and PrimaryBid offering [2][32] - The private placement and PrimaryBid offering are expected to close on 26 November 2025, with trading of Transgene shares suspended on that day [6][29][20] Use of Proceeds - Approximately 70% of the net proceeds will be allocated to accelerate the myvac® program, including ongoing clinical trials and manufacturing optimization [7][4] - About 20% will be used for R&D costs related to the myvac® program and other clinical trials, while the remainder will cover general administrative expenses [7][4] Financial Position - Prior to the fundraising, Transgene had €11.1 million in cash and a drawing capacity of €8.7 million on the Current Account Advance [8] - Following the completion of the Reserved Capital Increase, the Current Account Advance Agreement will be terminated, enhancing the company's financial stability [9][32] Expected Milestones - Key milestones for the myvac® platform include reporting important data in 2026 and 2027, with potential initiation of a Phase 3 trial in head and neck cancer [3][11][13]